X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (77) 77
rheumatology (77) 77
humans (73) 73
female (53) 53
male (51) 51
children (50) 50
child (47) 47
juvenile idiopathic arthritis (36) 36
arthritis, juvenile - drug therapy (34) 34
rheumatoid-arthritis (34) 34
adolescent (33) 33
article (33) 33
retrospective studies (31) 31
pediatrics (29) 29
abridged index medicus (28) 28
antirheumatic agents - therapeutic use (27) 27
child, preschool (27) 27
arthritis (23) 23
etanercept (21) 21
risk factors (21) 21
methotrexate (20) 20
rheumatoid arthritis (20) 20
treatment outcome (20) 20
tumor necrosis factor-alpha - antagonists & inhibitors (20) 20
therapy (19) 19
efficacy (18) 18
safety (18) 18
infliximab (17) 17
cohort studies (16) 16
united states (16) 16
diseases of the musculoskeletal system (15) 15
double-blind (14) 14
patients (14) 14
aged (13) 13
antirheumatic agents - adverse effects (12) 12
middle aged (12) 12
risk (12) 12
antibodies, monoclonal - therapeutic use (11) 11
arthritis, juvenile - diagnosis (11) 11
arthritis, rheumatoid - drug therapy (11) 11
health aspects (11) 11
research (11) 11
adalimumab (10) 10
adult (10) 10
drug therapy (10) 10
incidence (10) 10
infant (10) 10
management (10) 10
methotrexate - therapeutic use (10) 10
prevalence (10) 10
disease (9) 9
psoriasis (9) 9
registries (9) 9
antibodies, monoclonal, humanized - therapeutic use (8) 8
arthritis, juvenile - epidemiology (8) 8
arthritis, juvenile - pathology (8) 8
care and treatment (8) 8
tumor necrosis factor (8) 8
united states - epidemiology (8) 8
analysis (7) 7
classification (7) 7
dosage and administration (7) 7
glucocorticoids (7) 7
immunology and allergy (7) 7
infection (7) 7
inflammatory bowel disease (7) 7
macrophage activation syndrome (7) 7
medicare (7) 7
pediatric rheumatology (7) 7
pediatrics, perinatology, and child health (7) 7
proportional hazards models (7) 7
severity of illness index (7) 7
trial (7) 7
uveitis (7) 7
anti-inflammatory agents, non-steroidal - therapeutic use (6) 6
arthritis, juvenile - complications (6) 6
biological products - adverse effects (6) 6
complications and side effects (6) 6
criteria (6) 6
databases, factual (6) 6
diagnosis (6) 6
disease-activity (6) 6
drug therapy, combination (6) 6
factor-alpha antagonists (6) 6
follow-up studies (6) 6
hospitalization - statistics & numerical data (6) 6
immunocompromised host (6) 6
injections, intra-articular (6) 6
long-term safety (6) 6
lupus (6) 6
placebo-controlled trial (6) 6
rituximab (6) 6
skin and connective tissue diseases (6) 6
systemic lupus erythematosus (6) 6
tumor necrosis factor-tnf (6) 6
ultrasound (6) 6
abatacept (5) 5
anakinra (5) 5
antibodies, monoclonal - adverse effects (5) 5
antirheumatic agents - administration & dosage (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


F1000Prime Reports, ISSN 2051-7599, 04/2014, Volume 6, p. 21
Systemic juvenile idiopathic arthritis (JIA) is an autoinflammatory condition that is distinct from other forms of childhood arthritis. Recently, biologic... 
Journal Article
Journal of Oral and Maxillofacial Surgery, ISSN 0278-2391, 06/2019, Volume 77, Issue 6, pp. 1180 - 1186
Sarcoidosis is a multisystem granulomatous disease of unknown etiology that commonly affects the lungs, lymph nodes, and skin. The disease often presents in... 
Pediatrics | Children | College teachers | Health aspects | Teenage girls
Journal Article
Journal Article
Arthritis & Rheumatology, ISSN 2326-5191, 01/2016, Volume 68, Issue 1, pp. 56 - 66
Journal Article
Pediatric Rheumatology, ISSN 1546-0096, 12/2019, Volume 17, Issue 1, pp. 1 - 8
Abstract Background Evidence remains contradictory regarding second-line therapy in patients with Kawasaki disease (KD) refractory to initial intravenous... 
Infliximab | IVIg-refractory Kawasaki disease | Coronary artery aneurysm
Journal Article
Emerging Infectious Diseases, ISSN 1080-6040, 09/2011, Volume 17, Issue 9, pp. 1664 - 1669
To investigate the epidemiology and geographic distribution of histoplasmosis, coccidioidomycosis, and blastomycosis in older persons in the United States, we... 
ELDERLY PERSONS | HISTOPLASMOSIS | ARIZONA | INFECTIOUS DISEASES | USA | COCCIDIOIDOMYCOSIS | BLASTOMYCOSIS | SURVEILLANCE | SENSITIVITY | OPPORTUNISTIC INFECTIONS | HOSPITALIZATIONS | IMMUNOLOGY | Mycoses | Aged | Research | Diagnosis | Health aspects | Epidemiology | Risk factors | endemic mycoses | coccidioidomycosis | blastomycosis | histoplasmosis | fungi | rheumatoid arthritis
Journal Article
Arthritis Care & Research, ISSN 2151-464X, 11/2017, Volume 69, Issue 11, pp. 1617 - 1619
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 07/2018, Volume 77, Issue 7, pp. 1012 - 1016
Journal Article
Journal Article
JAMA Dermatology, ISSN 2168-6068, 02/2016, Volume 152, Issue 2, pp. 164 - 172
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2015, Volume 74, Issue 6, pp. 1065 - 1071
Background The risk of subsequent infections in rheumatoid arthritis (RA) patients who receive biologic therapy after a serious infection is unclear. Objective... 
infection | MODIFYING ANTIRHEUMATIC DRUGS | biologics | ADALIMUMAB | EFFICACY | SAFETY | abatacept | RHEUMATOLOGY | rheumatoid arthritis | anti-TNF therapy | ANTITUMOR-NECROSIS-FACTOR | SERIOUS BACTERIAL-INFECTIONS | FACTOR-ALPHA ANTAGONISTS | AGENTS | INFLIXIMAB | rituximab | United States | Humans | Hospitalization - statistics & numerical data | Antibodies, Monoclonal - therapeutic use | Male | Risk | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Infliximab | Arthritis, Rheumatoid - drug therapy | Aged, 80 and over | Immunoconjugates - therapeutic use | Female | Antirheumatic Agents - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Medicare | Arthritis, Rheumatoid - epidemiology | Proportional Hazards Models | Sepsis - epidemiology | Immunoglobulin G - therapeutic use | Rituximab | Soft Tissue Infections - epidemiology | Urinary Tract Infections - epidemiology | Aged | Respiratory Tract Infections - epidemiology | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Cohort Studies | Infection | Hospital patients | Usage | Care and treatment | Biological products | Rheumatoid arthritis | Health aspects | Risk factors | Studies | Pharmacy | Tumor necrosis factor-TNF | Infections | Prescription drug plans | Drug dosages | Cancer therapies | Skin cancer
Journal Article
The Journal of rheumatology, ISSN 0315-162X, 02/2019, Volume 46, Issue 2, pp. 124 - 126
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 11/2014, Volume 73, Issue 11, pp. 1942 - 1948
Objectives To determine among patients with autoimmune diseases in the USA whether the risk of non-viral opportunistic infections (OI) was increased among new... 
DMARDs (biologic) | Infections | Tuberculosis | Rheumatoid Arthritis | TNF-alpha | RHEUMATOID-ARTHRITIS | PNEUMOCYSTIS PNEUMONIA | RISK-FACTORS | SERIOUS BACTERIAL-INFECTIONS | FACTOR-ALPHA ANTAGONISTS | GRANULOMATOUS INFECTIONS | BRITISH-SOCIETY | RHEUMATOLOGY | INFLIXIMAB | ANTIBODY THERAPY | MYCOBACTERIAL DISEASES | United States - epidemiology | Biological Therapy - methods | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Opportunistic Infections - chemically induced | Arthritis, Rheumatoid - drug therapy | Antirheumatic Agents - adverse effects | Adult | Biological Products - adverse effects | Female | Opportunistic Infections - immunology | Retrospective Studies | Autoimmune Diseases - drug therapy | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Autoimmune Diseases - epidemiology | Opportunistic Infections - epidemiology | Arthritis, Rheumatoid - epidemiology | Autoimmune Diseases - immunology | Biological Therapy - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Immunocompromised Host | Arthritis, Rheumatoid - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Complications and side effects | Care and treatment | Opportunistic infections | Tumor necrosis factor inhibitors | Dosage and administration | Autoimmune diseases | Risk factors | Codes | Bacterial infections | Medicare | Lung diseases | Inflammatory bowel disease | Immunotherapy | Pharmacy | Gangrene | Tumor necrosis factor-TNF | Medicaid | Viral infections | Pharmaceuticals
Journal Article